MARKET

PHGE

PHGE

BiomX Inc
AMEX

Real-time Quotes | Nasdaq Last Sale

9.25
+0.21
+2.32%
Closed 16:00 12/13 EST
OPEN
9.00
PREV CLOSE
9.04
HIGH
9.35
LOW
9.00
VOLUME
1.72K
TURNOVER
--
52 WEEK HIGH
11.90
52 WEEK LOW
6.13
MARKET CAP
80.94M
P/E (TTM)
330.36
1D
5D
1M
3M
1Y
5Y

Buy or sell shares of PHGE and other stocks commission-free!

Open a Webull account and fund it to get a free stock

EPS

PHGE News

  • BiomX Announces Completion of Enrollment for Double-Blind, Placebo-Controlled Clinical Study of BX001 in Acne-Prone Skin
  • Business Wire.12/02 12:30
  • BiomX Presents Preclinical Results of its Phage Therapy Program Targeting Primary Sclerosing Cholangitis
  • Business Wire.11/12 12:30
  • Stone Street Group Initiates Coverage On BiomX Inc.
  • PR Newswire.11/12 12:25
  • BiomX Appoints Russell G. Greig, Ph.D, as Chairman of the Board of Directors and Lynne Sullivan as Board Director
  • Business Wire.11/04 22:38

More

Industry

Biotechnology & Medical Research
+1.07%
Pharmaceuticals & Medical Research
-0.32%

Hot Stocks

Name
Price
%Change

About PHGE

BiomX Inc., formerly Chardan Healthcare Acquisition Corp., is a microbiome company. The Company is focused on developing both natural and engineered phage therapies. It develops therapies to target and destroy bacteria that affect the appearance of skin, as well as harmful bacteria in chronic diseases, such as inflammatory bowel disease (IBD), primary sclerosing cholangitis (PSC) and cancer. The Company discovers and validates bacterial targets and customizes phage compositions against the targets. Its pipeline includes BX001, BX002 and BX003. BX001 is a product candidate that improves the appearance of acne-prone skin. BX002 is a customized phage cocktail that eradicates bacterial targets associated with the onset of IBD. BX003 is a customized phage cocktail developed against specific strains of Klebsiella pneumoniae (Kp).
More

Webull offers Biomx Inc (PHGE) stock price, real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, stock news, and many more online research tools to help you make informed decisions.